

This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): Via, Jack Dalla; Owen, Patrick J.; Daly, Robin M.; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Foulkes, Stephen J.; Millar, Jeremy L.; Murphy, Declan G.; Fraser, Steve F.

Title: Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT

Year: 2021

Version: Accepted version (Final draft)

Copyright: © 2021 American College of Sports Medicine

Rights: In Copyright

Rights url: <http://rightsstatements.org/page/InC/1.0/?language=en>

Please cite the original version:

Via, J. D., Owen, P. J., Daly, R. M., Mundell, N. L., Livingston, P. M., Rantalainen, T., Foulkes, S. J., Millar, J. L., Murphy, D. G., & Fraser, S. F. (2021). Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT. *Medicine and Science in Sports and Exercise*, 53(10), 2054-2065.
<https://doi.org/10.1249/mss.0000000000002682>

Medicine & Science IN Sports & Exercise

The Official Journal of the American College of Sports Medicine

www.acsm-msse.org

. . . Published ahead of Print

Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-month RCT

Jack Dalla Via¹, Patrick J. Owen¹, Robin M. Daly¹, Niamh L. Mundell¹,
Patricia M. Livingston², Timo Rantalainen^{1,3}, Stephen J Foulkes^{1,4}, Jeremy L. Millar⁵,
Declan G. Murphy^{6,7}, Steve F. Fraser¹

¹Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia; ²Deakin University, Faculty of Health, Geelong, Victoria, Australia; ³Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland; ⁴Sports Cardiology Lab, Clinical Research Domain, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; ⁵Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia; ⁶Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ⁷Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia

Accepted for Publication: 16 March 2021

Medicine & Science in Sports & Exercise®. Published ahead of Print contains articles in unedited manuscript form that have been peer reviewed and accepted for publication. This manuscript will undergo copyediting, page composition, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered that could affect the content.

Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-month RCT

Jack Dalla Via¹, Patrick J. Owen¹, Robin M. Daly¹, Niamh L. Mundell¹,
Patricia M. Livingston², Timo Rantalainen^{1,3}, Stephen J Foulkes^{1,4}, Jeremy L. Millar⁵,
Declan G. Murphy^{6,7}, Steve F. Fraser¹

¹Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia; ²Deakin University, Faculty of Health, Geelong, Victoria, Australia; ³Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland; ⁴Sports Cardiology Lab, Clinical Research Domain, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; ⁵Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia; ⁶Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ⁷Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia

Corresponding author:

Dr Jack Dalla Via

School of Exercise and Nutrition Sciences, Deakin University

221 Burwood Highway, Burwood, Melbourne, Victoria, 3125, Australia

Telephone: +61 3 9246 8347

Email: j.dallavia@deakin.edu.au

ORCID iD: 0000-0002-1815-0838

The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of the present study do not constitute endorsement by ACSM.

Funding: The study received in-kind support from YMCA Victoria, Ostelin and Omniblend. Facilities, equipment and internal funding were provided by Deakin University.

Conflicts of interest: Robin M. Daly has received funding from a Primary Growth Partnership grant via the Ministry of Primary Industries in New Zealand with Fonterra Co-operative Group Ltd. Declan G. Murphy has received honoraria for advisory board and speaker duties from Astellas, Janssen, Astra Zeneca, Bayer, Ferring and Ipsen. All other authors declare that they have no conflicts of interest.

ABSTRACT

Purpose: Androgen deprivation therapy (ADT) for prostate cancer (PCa) has multiple adverse effects on musculoskeletal health. This 12-month randomised controlled trial aimed to assess the effects of multi-component exercise training combined with whey protein, calcium and vitamin D supplementation on bone mineral density (BMD), structure and strength, body composition, muscle strength and physical function in ADT-treated men.

Methods: Seventy ADT-treated men were randomised to exercise plus supplementation (Ex+Suppl; n=34) or usual care (Control; n=36). Ex+Suppl involved thrice weekly progressive resistance training plus weight-bearing impact exercise with daily multi-nutrient supplementation. Primary outcomes were DXA hip and spine areal BMD. Secondary outcomes included: tibia and radius pQCT volumetric BMD, bone structure and strength; DXA body composition; pQCT muscle and fat cross-sectional area and muscle density; muscle strength and physical function.

Results: Sixty men (86%) completed the study. Mean exercise and supplement adherence were 56% and 77%, respectively. There were no effects of the intervention on bone or body composition outcomes. Ex+Suppl improved leg muscle strength (net difference [95% CI] 14.5% [-0.2, 29.2], P=0.007) and dynamic mobility (four-square-step test time, -9.3% [-17.3, -1.3], P=0.014) relative to controls. Per-protocol analysis of adherent participants ($\geq 66\%$ exercise, $\geq 80\%$ supplement) showed Ex+Suppl preserved femoral neck aBMD (1.9% [0.1, 3.8], P=0.026) and improved total body lean mass (1.0 kg [-0.23, 2.22], P=0.044) relative to controls.

Conclusion: Exercise training combined with multi-nutrient supplementation had limited effect on ameliorating the adverse musculoskeletal consequences of ADT, likely related to the modest intervention adherence.

Key Words: Exercise, Nutrition, Cancer, Bone, Muscle, Androgen Deprivation Therapy

ACCEPTED

INTRODUCTION

Androgen deprivation therapy (ADT) is commonly used to treat advanced or metastatic prostate cancer (PCa) and is shown to improve survival in appropriately selected patients (1), but is associated with multiple adverse effects, particularly regarding musculoskeletal health (1, 2). Within the first year of treatment, 1-5% losses in hip and spine areal bone mineral density (aBMD) (3, 4), a 6-13% deterioration in cortical bone structure and vBMD and a 2-4% reduction in trabecular vBMD (5), a 2-4% decline in lean mass and a 7-14% increase in fat mass along with impaired muscle strength and physical function have been reported (3, 6). Clinically, these marked musculoskeletal changes likely contribute to the reported 39-46% increased fracture risk in ADT-treated men (7, 8).

Exercise training is widely recommended to combat the adverse effects of ADT (4, 9), with aerobic and/or progressive resistance training (PRT) shown to effectively reduce fat mass gains and improve aerobic fitness, fatigue, muscle mass, strength, function and quality of life in ADT-treated men (2, 9). However, the effects of exercise on bone health are largely inconclusive. While some interventions have demonstrated that PRT and impact exercise can attenuate hip and spine aBMD loss in ADT-treated men (10, 11), most report negligible skeletal effects (12-15). Few studies have assessed the effects of exercise on other determinants of bone strength beyond aBMD in ADT-treated men, including cortical and trabecular bone density and cortical bone structure. This is important because changes in these skeletal determinants can influence bone strength without measurable changes in aBMD (16).

Calcium and vitamin D supplementation are recommended in clinical care guidelines for ADT

patients to mitigate bone loss (17), but few intervention trials have investigated their effects on bone health or fracture risk in ADT-treated men. In healthy older adults, daily calcium plus vitamin D supplementation has been shown to modestly improve or attenuate bone loss and reduce fracture risk (18, 19). Increased dietary protein intake and vitamin D in combination with exercise, particularly PRT, are recommended to prevent age-related muscle loss in older adults (20). Indeed, there is evidence that supplementation with whey protein or a multi-nutrient supplement containing protein with vitamin D can enhance the effects of PRT on muscle mass and strength in older men and women (21, 22). Given that exercise alone has not been shown to consistently mitigate bone or muscle loss in ADT-treated men, interventions combining exercise with nutritional support specifically targeted at both bone and muscle may provide the greatest benefits.

The primary aim of this 12-month RCT was to investigate whether a community-based, multi-component exercise program combined with a protein, calcium and vitamin D enriched supplement could improve hip and lumbar spine (LS) aBMD in ADT-treated men. It was hypothesised that the intervention would attenuate the expected decline in aBMD, relative to controls. Secondary aims were to investigate the effects of the intervention on pQCT assessed cortical and trabecular vBMD, bone structure and strength at the distal and proximal tibia and radius, as well as body composition, muscle strength and physical function.

METHODS

Study Design

This was a two-arm, 12-month RCT in which 70 men with PCa treated with ADT were

randomised to either multi-component exercise training combined with multi-nutrient supplementation (Ex+Suppl) or a usual care control (CON) group. The study protocol has been described previously (23). Briefly, participants were randomised 1:1 following baseline assessment, stratified by age (<65 or ≥65 years) and BMI (<30 and ≥30 kg/m²) using a computer-generated random number sequence, by an independent researcher into one of the two groups. Outcomes were assessed at baseline, six and 12 months. The study was approved by the Deakin University Human Research Ethics Committee, Alfred Health and Peter MacCallum Cancer Centre, and registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12614000317695).

Participants

Men aged 50-85 years with PCa treated with ADT were recruited between April 2014 and November 2017 via clinician referral, PCa support groups and local newspaper advertisements throughout Victoria, Australia. Eligible participants were men with histologically diagnosed PCa currently being treated with pharmacological ADT for longer than 12 weeks. Participants were excluded if they could not complete surveys in the English language, had any disorder(s) known to affect bone, calcium or vitamin D metabolism (other than hypogonadism), were currently receiving pharmacological intervention known to affect bone metabolism (other than ADT), had supplemented with protein, calcium (>600 mg/day) or vitamin D (>1000 IU/day) in the past three months, had undertaken PRT (>1 session/week) or regular weight-bearing impact exercise (>150 min/week) in the past three months, were current smokers, weighed >159 kg or had any absolute contraindications to exercise testing (24). All eligible participants obtained medical approval from their physician and gave written informed consent prior to participation. The study

was conducted in accordance with the Declaration of Helsinki.

Intervention

Exercise training program

A detailed description of the exercise program has been previously reported (23). Briefly, participants were prescribed two gym-based sessions and one home-based session per week. Each gym-based session (□60 minutes) consisted of 5-10 minutes of aerobic training (stationary cycling, treadmill walking, rowing) as part of the warm-up, 5-6 PRT exercises (two sets, 8-12 repetitions at moderate to hard intensity) predominantly targeting the hip and spine using machine and free weights, three weight-bearing impact exercises (three sets, 10-20 repetitions) predominantly targeting the lower-limb (e.g. jumping, hopping, step-ups), two challenging balance/functional exercises (two sets of 30-60 seconds or a given number of repetitions) and two core stability exercises (two sets, 10-15 repetitions). Progressive overload was applied to PRT by increasing the resistance, and to impact exercises by increasing the height of jumps, adding additional weight, increasing the rate of impact-loading or adding multi-directional movement patterns. During the first six months, two weekly gym-based sessions were supervised by an accredited exercise physiologist in a community-based health and fitness facility. For the final six months, one weekly gym-based session was supervised. The home-based exercise program (20-60 minutes) followed a similar structure and exercises to the gym-based sessions but used body weight and resistance bands. Participants first practiced the home exercises in the gym and were provided with instructions and an exercise card to complete at home. All exercise programs were individually tailored with modifications made based on factors such as bone metastases or comorbid conditions.

Multi-nutrient nutritional supplement

The multi-nutrient supplement consisted of a whey protein-, calcium- and vitamin D-enriched drink (powder mixed with 150ml of water) combined with a single vitamin D tablet. Each sachet contained approximately 440kJ energy, 25g whey-protein concentrate 80% (WPC80), containing approximately 2.4g leucine, 1200mg calcium carbonate and 1000IU vitamin D (Omniblend, Campbellfield, Victoria, Australia). The vitamin D tablet contained 1000IU (Ostelin, Macquarie Park, NSW, Australia). Participants were asked to take one sachet every morning, either before breakfast on non-training days or within 1–2 hours of exercise on training days. Participants were advised to consume the supplement in addition to their regular diet.

Usual Care Control Group

Participants allocated to usual care received ongoing care from their physician/specialist and a single 1000IU vitamin D tablet per day.

Outcome Measures

Areal BMD

Lumbar spine (L1-L4) and proximal femur (femoral neck [FN] and total hip) aBMD (g/cm^2) were assessed using DXA (Lunar iDXA, GE Lunar Corp., Madison, WI, USA). The prevalence of osteoporosis (T-score ≤ -2.5) or osteopenia (T-score between -2.5 and -1.0) was based on the World Health Organization criteria (25) from the lowest T-score at any site. The short-term coefficient of variation (CV) for aBMD ranged from 0.6-1.0% within our laboratory.

Volumetric BMD, bone structure and strength

Proximal (66%) and distal (4%) sites of the non-dominant radius and dominant tibia were scanned using pQCT (XCT 3000, Stratec Medizintechnik GmbH, Pforzheim, Germany). Cortical volumetric BMD (mg/cm^3), bone structure (total, cortical and medullary area [mm^2]) and strength (density-weighted polar cross-sectional moment of inertia [I_{polar} , mg/cm]) at proximal sites, as well as trabecular vBMD (mg/cm^3) and strength (bone strength index [BSI, mg^2/mm^4]) at distal sites were assessed. The slice thickness was 1mm and voxel size was 0.5mm at a scanning speed of 20mm/s. pQCT images were analysed in the Fiji image analysis platform (26) using the BoneJ plugin (27) as previously reported (28). Distal radius and tibia (4%) total bone area were analysed based on thresholding at $169\text{mg}/\text{cm}^3$. Trabecular density was determined by peeling single layers of pixels until 45% of the total bone area remained. BSI was calculated as total area multiplied by the square of total vBMD (29). For the 66% proximal radius and tibia, the periosteal surface was determined based on a threshold of $280\text{mg}/\text{cm}^3$, and cortical bone a threshold of $550\text{mg}/\text{cm}^3$. Medullary area was calculated by subtracting cortical area from total area. I_{polar} was determined using the bone threshold of $480\text{mg}/\text{cm}^3$ (30). Scans were excluded according to the visual inspection rating scale of participant movement (31, 32). Short-term CVs were 0.9-2.2% for the 4% radius, 0.7-2.5% for the 4% tibia and 0.6-1.8% for the 66% tibia outcomes (33).

Body composition

Total and regional (arms, legs, trunk and appendicular) lean mass and fat mass were assessed by DXA as described above. The short-term CV for lean and fat mass ranged from 1.0-1.7%. Muscle and subcutaneous fat cross-sectional area (CSA) and muscle density (as a measure of

intermuscular adiposity) at the proximal (66%) radius and tibia were assessed using pQCT. Thresholds of -40 to $+40$ mg/cm^3 hydroxyapatite density were used for estimating subcutaneous fat CSA. Muscle CSA was estimated by subtracting the total bone CSA and subcutaneous fat CSA from the total area of the 66% tibia or radius. The following CVs have been reported for muscle CSA (radius, 2.1-5.3%; tibia, 2.5-3.7%), muscle density (radius, 1.4-3.2%; tibia 0.7-3.2%) and subcutaneous fat CSA (radius, 2.4-3.2%; tibia, 6.0-6.3%) (34).

Muscle strength and function

As reported in detail previously (23), maximum muscle strength of the lower body (leg press), chest (chest press) and back (seated row) was assessed using three-repetition maximum (3-RM) protocols. Maximal grip strength was assessed using a digital grip-strength dynamometer (Jamar Plus Digital, Lafayette Instrument Company, IN, USA). Physical function was assessed via the 30-second sit-to-stand test, timed-up-and-go (TUG) test with a cognitive task (counting backwards by 3 from a random number), four-square step test (FSST), Berg Balance Scale, 4-m usual walk (to assess gait speed) and 400-m walk. Detailed methodology for each test has been described previously (23).

Demographic, health and lifestyle information

A questionnaire was used to obtain background demographic, clinical and lifestyle information from participants, including cultural background, PCa and ADT use details, medical conditions (past and current), prescription and non-prescription medication use (type and dose) and history of falls in the previous 12 months and fractures since the age of 45.

Anthropometry, physical activity and diet

Height and weight were assessed using a portable stadiometer (SECA, Hamburg, Germany) and scales (A&D, Tokyo, Japan), respectively. Body mass index (BMI) was calculated as body mass (kg) divided by height (m) squared (kg/m^2). The Community Healthy Activities Model Programme for Seniors (CHAMPS) physical activity questionnaire was used to assess habitual physical activity levels (35). Diet was assessed using a 24-hour food recall and analysed using Australia-specific dietary analysis software (FoodWorks, Xyris software, Highgate Hills, Australia).

Adherence

Exercise adherence was assessed using exercise cards for gym-based sessions or self-reported training diaries for home-based sessions. Supplement adherence was assessed by counting sachets and vitamin D capsules returned at six and 12 months and cross-checked against supplement calendars completed by participants.

Adverse events

Adverse events, defined as any unfavourable or unintended health-related event or issue that developed or worsened during the study period as a result of the intervention, were recorded at exercise sessions for the Ex+Suppl group and at follow-up testing sessions for controls.

Blood biomarkers

Fasted, resting morning blood samples were collected at a commercial pathology clinic, with serum aliquots stored at -80°C . Blood samples were assessed immediately for total prostate

specific antigen (PSA) and high-sensitivity C-reactive protein (CRP) using standard techniques. Serum 25-hydroxyvitamin D [25(OH)D] was assessed using a LIAISON® 25OH-Vitamin D assay (DiaSorin, Stillwater, MN, USA) and serum insulin-like growth factor 1 (IGF-1) using a LIAISON® IGF-1 one-step sandwich chemiluminescence immunoassay (DiaSorin, Saluggia, VC, Italy). All samples were analysed in duplicate at Monash Health (Monash Medical Centre, Clayton, VIC, Australia) at the completion of the study.

Sample Size Calculations

Based on previous research (5, 36), it was estimated that 29 participants per group would provide 90% power ($P < 0.05$, two-tailed) to detect a net difference of 3.5-4.0% (assuming a SD of 4.0) in the primary outcomes of proximal femur and LS aBMD. For secondary pQCT bone structure outcomes, it was estimated that 39 participants in each group would provide 90% power ($P < 0.05$, two-tailed) to detect a 50% reduction in the previously reported 11.5-12.5% annual losses in radial and tibia cortical area (assuming a SD of 8.0) (5). Assuming a 30% dropout, we aimed to recruit and randomise 51 participants per group.

Statistical Analysis

Data were analysed using Stata statistical software (Version 15.0, Stata, College Station, TX, USA). Primary analyses were completed using an intention-to-treat approach. Per protocol analyses were also completed including participants with $\geq 66\%$ exercise adherence and $\geq 80\%$ nutritional supplement adherence. All data were screened for outliers and assessed for normality by visual inspection of histograms of the residuals. Linear mixed-effects models with random effects (participants) were used to assess within-group changes over time and group-by-time

interactions (both fixed effects) at six and 12 months. Generalised linear mixed models (GLMM) with a gamma distribution and log-link were used for variables that were non-normally distributed. Baseline measures are presented as means \pm SD for continuous data or frequency and percentage for categorical data, unless specified otherwise. Mean change in outcomes with 95% confidence interval are presented as either absolute change or as percentage change from baseline. Net differences between groups for the change from baseline to six and 12 months were calculated as the change within the control group subtracted from the change within the intervention group. For non-normally distributed data that was assessed using GLMMs, the data was log transformed so that the percentage change could be calculated as the absolute change in natural log transformed values multiplied by 100 (37). No data imputation was made for missing data as the linear mixed models can handle missing data with maximum likelihood estimation. An alpha level of 0.05 was used to determine statistical significance.

RESULTS

Participant characteristics

In total, 214 men expressed interest in the study from which 70 were randomised (Figure 1). Recruitment ceased after 43 months, prior to reaching our target of 102 men, due to funding constraints given a slow recruitment rate. As shown in Table 1, on average the men were aged 71 years, with 53% and 30% classified as overweight and obese, respectively, 89% reporting the presence of co-morbidities (mean number 2.6), and 50% and 6% classified as having osteopenia and osteoporosis, respectively. Median time since PCa diagnosis was 3.3 years and median duration of ADT use was 12 months. Overall, 64% of men were classified as having advanced PCa and 29% as having bone metastases, with 49% reported having a previous prostatectomy,

69% previous radiotherapy and 16% previous chemotherapy.

Attrition and adherence

Sixty (86%) men completed the study (Ex+Suppl, n=31; Control, n=29). One participant in Ex+Suppl did not commence the exercise program due to a perceived lack of time, while five men discontinued training (four within three months, one after nine months) due to health issues unrelated to the study (n=3), perceived lack of time (n=1) or personal reasons (n=1). Four of these six men continued taking the nutritional supplement for the duration of the study, and five of the six agreed to attend follow-up testing sessions. Mean \pm SD exercise adherence was 56% \pm 30% (supervised 65% \pm 25%; unsupervised 49% \pm 38%). Mean multi-nutrient supplement adherence was 77% \pm 30%.

Safety, tolerability and adverse events

There were no serious adverse events related to the intervention. There were 21 musculoskeletal complaints reported by 14 (41%) participants in Ex+Suppl. Most complaints (n=19) were minor requiring no treatment and led to between one and four missed or modified sessions. Two participants experienced exacerbation of existing knee injuries and trained with a modified program for six weeks. Additionally, three participants stopped taking the nutritional supplement within the first six months due to gastrointestinal complaints that they attributed to the supplement.

Prostate cancer treatment

At baseline, median ADT duration was five months higher in the control compared to Ex+Suppl

group (Table 1). Eight men (1 Ex+Suppl; 7 CON) discontinued ADT treatment during the first 6 months of the intervention and a further eight (4 Ex+Suppl; 4 CON) discontinued treatment between 6 and 12 months. The total number of men in each group that discontinued ADT (5 Ex+Suppl; 11 CON) did not differ statistically ($P=0.114$). During the study period, four participants (all Ex+Suppl) commenced radiation therapy, six participants (5 Ex+Suppl; 1 CON) commenced chemotherapy, and seven participants (4 Ex+Suppl; 3 CON) were prescribed adjuvant anti-androgen medication, to be taken concomitantly with existing gonadotropin-releasing hormone agonists. The results were unchanged when ADT duration, whether participants discontinued ADT, had bone metastasis at baseline, commenced radiation therapy, commenced chemotherapy or were prescribed anti-androgen medication during the study, were included as covariates in the analyses. Thus the unadjusted results are presented below.

Diet and physical activity

Baseline mean dietary calcium intake was 841 mg/d, with 51 (73%) men classified as having intakes below the Australian Recommended Dietary Intake (RDI). There were no significant between-group differences over time or within-group changes in habitual physical activity and daily energy, carbohydrate, protein, fat or calcium intake (excluding the supplement) (see Supplementary Table 1, Supplemental Digital Content, appendix, <http://links.lww.com/MSS/C321>), except for an increase in habitual physical activity within the control group at 12 months (mean change, 453 kJ/day [95% CI 70, 835], $P=0.040$).

Blood biomarkers

Mean baseline serum 25(OH)D levels were 69.8 nmol/L, with 12 (17%) men having insufficient

vitamin D levels (<50 nmol/L). Ex+Suppl had a greater increase in serum 25(OH)D compared to controls after six months (net difference 12.4 nmol/L [95% CI 8.9, 19.9], P=0.001), but not 12 months (see Supplementary Table 2, Supplemental Digital Content, appendix, <http://links.lww.com/MSS/C321>). There were no significant between-group effects or within-group changes in serum IGF-1, hs-CRP or PSA after six or 12 months (see Supplementary Tables 2-3, Supplemental Digital Content, appendix, <http://links.lww.com/MSS/C321>).

DXA areal BMD

There were no significant effects of the intervention on LS or proximal femur aBMD (Table 2), with both groups experiencing a significant 1.1% to 1.9% loss in FN and total hip aBMD after 12 months.

pQCT volumetric BMD, bone structure and strength

There were no significant effects of the intervention on distal (4%) tibia or radius trabecular vBMD or BSI after six or 12 months (Table 3), with both groups experiencing similar losses in distal tibia (3.8-4.5%) and radius (9.2-10.6%) BSI, and distal radius (2.7-2.9%) trabecular vBMD after 12 months. There were also no significant intervention effects on proximal (66%) tibia or radius cortical vBMD, bone structure or I_{polar} after six or 12 months, except for a 1.4% net benefit of Ex+Suppl on proximal radius cortical vBMD after six months (P=0.035). Tibia and radius cortical area declined similarly in each group after 12 months with no change in total bone area, indicating that cortical bone loss was due to increased endocortical resorption.

Body composition

There were no significant between-group effects on weight or any DXA or pQCT body composition measure after six or 12 months (Table 4; see Supplementary Table 4, Supplemental Digital Content, appendix, <http://links.lww.com/MSS/C321>), except that leg fat mass increased in Ex+Suppl compared to controls at 12 months (net difference 0.34kg [95% CI -0.06, 0.74], $P=0.018$), proximal tibia and radius subcutaneous fat CSA increased in Ex+Suppl compared to controls at 12 months (net differences 9.8% [95% CI 0.8, 18.8], $P=0.030$ and 9.0% [95% CI 1.4, 16.7], $P=0.004$, respectively), and proximal radius muscle density decreased in Ex+Suppl compared to controls at 12 months (net difference -1.7% [95% CI -3.3, -0.2], $P=0.012$).

Muscle strength and function

Lower body muscle strength (leg press) improved in Ex+Suppl compared to controls at six months (net difference 11.0% [95% CI 0.1, 21.9], $P=0.048$) and 12 months (net difference 14.5% [95% CI -0.2, 29.2], $P=0.007$) (Table 5). Chest press muscle strength increased in Ex+Suppl compared to controls at six months (net difference 10.7% [95% CI 0.2, 21.1], $P=0.024$), but not at 12 months. There was no effect of the intervention on back (seated row) or grip strength or any measure of physical function (Table 5), except that FSST performance improved in Ex+Suppl compared to controls at six months (net difference -10.3%, (95% CI -17.1, -3.4), $P=0.003$) and 12 months (net difference -9.3% [95% CI -17.3, -1.3], $P=0.014$).

Per protocol analysis

All results for the per-protocol analysis (exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$ [$n=11$]) remained unchanged, except for the following (see Supplementary Tables 5-8,

Supplemental Digital Content, appendix, <http://links.lww.com/MSS/C321>): 1) there was a net beneficial effect of Ex+Suppl relative to controls on FN aBMD at 12 months (net difference 1.9% [95% CI 0.1, 3.8], P=0.026), which was driven by a significant loss in controls (-1.8% [95% CI -2.9, -0.7], P<0.001); 2) there was no effect of Ex+Suppl on proximal radius cortical vBMD; 3) total body lean mass increased in Ex+Suppl compared to controls at six months (net difference 1.2kg [95% CI 0.2, 2.1], P=0.021), which persisted after 12 months (net difference 1.0kg [95% CI -0.2, 2.2], P=0.044) (similar findings were observed for leg lean mass); and 4) weight increased in Ex+Suppl compared to controls after 12 months (net difference 1.9kg [95% CI -0.4, 4.1], P=0.039).

DISCUSSION

The main findings from this 12-month RCT was that a multi-component exercise program with a daily protein, calcium and vitamin D enriched supplement was largely ineffective for improving or maintaining bone density, structure or strength, body composition or physical function compared to usual care in men with prostate cancer treated with ADT. There was evidence to support a beneficial effect on FN aBMD and lean mass among men who were adherent to the intervention (exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$), but these findings must be interpreted with caution due to the small number of men (n=11) that achieved this level of adherence.

The lack of any significant effect of our intervention on aBMD measures is largely consistent with several previous 12-month interventions that have reported no or limited benefits of exercise (all incorporating PRT) alone on LS and proximal femur aBMD in ADT-treated men

(10, 12-15). While one three-arm, 12-month RCT in 154 ADT-treated men reported that PRT plus impact exercise, but not PRT plus aerobic training, attenuated LS aBMD loss relative to controls (-0.6% versus -1.8% , $P=0.035$), there were no long-term exercise benefits on proximal femur aBMD after 12 months (10). Similarly, the lack of effect on tibia or radius vBMD, bone structure or strength in our study is consistent with the only other known exercise RCT in ADT-treated men that used pQCT (12). Cormie and colleagues (12) reported no effect of three months of PRT and aerobic training on distal tibia total vBMD in 63 men commencing ADT, although a limitation of this study is the short duration which is insufficient to capture true physiological changes in bone given the typical bone remodelling cycle lasts approximately six months. However, several longer-term trials (8-18 months) in healthy older men have reported inconsistent findings regarding the effects of PRT and impact exercise training on (p)QCT-derived bone measures (38, 39). Collectively, findings from our trial and previous interventions suggest that there is currently little evidence to support multi-component exercise programs as an approach to attenuate ADT-related bone loss in men with PCa, particularly at the proximal femur.

A number of factors likely explain the lack of effect of our multi-faceted exercise and nutrition intervention on bone outcomes, despite our exercise program being modelled on the successful *Osteo-cise: Strong Bones for Life* community-based exercise program that significantly improved LS and FN aBMD by 1.0-1.1% in healthy older adults (36). Modest adherence to the exercise training in our study (mean 56% over 12 months) is likely a key reason, which is partly supported by our per-protocol analyses that revealed a significant positive effect (net 1.9% benefit) of the intervention on FN aBMD relative to controls. However, these findings must be

interpreted with caution given the relatively small number (n=11) of men from the intervention group that were included in the per-protocol analysis. There were also no intervention effects on other bone outcomes in the per-protocol analysis, suggesting that factors beyond just adherence contributed to the lack of effect on bone. For instance, modifications made for some participants due to PCa related factors, such as bone metastases and adverse effects associated with additional PCa treatments, limited the intensity and/or dose of exercise training or the specificity of the program to target clinically relevant skeletal sites. It is also possible that hypogonadism induced by ADT may have blunted the osteogenic response to exercise training. Testosterone suppression with ADT can lead to low estrogen levels, which is suggested to influence the minimal effective strain threshold required for bone adaptation and therefore the anabolic response of bone to loading (40). Consequently, a greater mechanical stimulus (strain) may be required to overcome this and elicit osteogenic adaptations in men with hypogonadism induced by ADT. Finally, men in the current study generally had sufficient dietary protein intakes, and calcium intakes were within the current Australian estimated average requirements, and vitamin D levels were replete, which may have limited potential additional exercise-related benefits of the nutritional supplement on bone (or muscle) outcomes.

The lack of any intervention effects on bone may also relate to negligible effects of the intervention on muscle-related outcomes, including lean mass, muscle CSA and muscle strength. The 0.5 kg non-significant net intervention related benefit to total body lean mass in our study was less than the significant 0.8 kg net benefits reported in two previous three to six month PRT and aerobic exercise interventions in ADT-treated men (41, 42), however several other PRT-related trials over three to 12 months in ADT-treated men also reported non-significant 0.3 to 0.7

kg net benefits to lean mass relative to controls (10, 12, 13, 43). The heterogeneity in reported skeletal muscle responses to PRT-related training in ADT-treated men may be attributed to a number of factors, including differences in training intensity and frequency, the inclusion of aerobic training which has been hypothesized to influence hypertrophic adaptations, and the timing of commencing exercise relative to the initiation of ADT (44). As with the bone outcomes, modest adherence to the intervention also likely contributed to the lack of marked muscle benefits. Indeed, our per-protocol analyses showed a net 1.0 to 1.2 kg intervention related benefit to total body lean mass after six and 12 months. However, there were no effects on pQCT assessed muscle CSA of the forearm or lower leg. Collectively, these findings may relate to the multi-component nature of our exercise program in which PRT was one of four key training elements and a greater dose or volume of PRT may be required to elicit skeletal muscle gains. This is supported by a meta-analysis reporting higher volume PRT programs were associated with the greatest benefits in lean mass among older adults (45). Furthermore, a meta-analysis of seven exercise RCTs in ADT-treated men found that low- to moderate-intensity PRT and aerobic training had no effect on lean mass, despite increasing muscle strength (44). It is also possible that the dose of whey protein provided (25g/d) in the nutritional supplement in our study may have been insufficient to enhance skeletal muscle adaptations in combination with the exercise program as there is some evidence from acute feeding studies that protein doses (whey or milk protein) of 30-40g post-exercise are required to maximally stimulate muscle protein synthesis (46, 47). However, there are mixed findings from meta-analyses of RCTs examining whether protein supplementation can enhance the effects of exercise (resistance training) on muscle mass or strength in older adults (48-50). As a result, there is no universal consensus on the optimal dose (or type or timing) of protein needed to enhance the effects of exercise on muscle mass and

strength in older adults or cancer survivors (51, 52).

Previous exercise studies in ADT-treated men have reported improved upper and lower body strength (10, 12, 41, 53), chair rise performance, gait speed and balance (12, 13, 41, 54). In our study, leg press muscle strength and dynamic balance assessed by the FSST, were the only outcomes that improved following exercise relative to controls. While it is possible that the lack of intervention effects on lean mass or muscle CSA contributed to the limited effects on other measures of muscle strength and physical function, the positive effects observed on the above outcomes supports the training principle of specificity as the exercise program focussed on lower body resistance exercises and challenging balance and mobility exercises. Nevertheless, it should be recognised that our net benefits to muscle strength (15%) and dynamic mobility (9%) were relatively modest, which may be likely due to the men included in the study being relatively well functioning at baseline.

Previous exercise interventions in ADT-treated men have reported either reduced fat mass (12, 42) or no changes over time relative to control groups (10, 13, 41), but no studies have examined the combined effects of exercise with nutritional supplementation. In older overweight/obese adults, there is evidence to support reduced fat mass and weight loss with whey protein supplementation alone or in combination with exercise (55, 56). Therefore the observed, albeit non-significant, 0.9 to 1.0 kg net increases in fat mass and body weight (and greater gains in forearm and lower leg subcutaneous fat CSA) in Ex+Suppl relative to controls after 12 months in our study were unexpected. While this could relate to the additional 440 kJ per day consumed from the supplement, all results remained unchanged when energy (kJ) from the nutritional

supplement (adjusted for supplement adherence) was factored into the daily dietary energy intake results. Although the observed net gain in fat mass in our study appears to contrast with findings from several previous exercise interventions in ADT-treated men (10, 12, 13, 41, 42), similar magnitude 0.9 to 1.1 kg within group increases have been reported following six to 12 month exercise interventions conducted in ADT-treated men (10, 14). It is important to note that men allocated to the intervention in our study were advised that the supplement was not to be taken as a meal replacement. Subsequent dietary analyses indicate that this occurred as mean habitual dietary intakes (excluding the supplement) were no different between groups at any timepoint. Given that weight and fat gain are common side-effects of ADT, further studies are needed to evaluate the effects of nutritional supplementation with exercise on body composition in ADT-treated men.

A strength of this study is that it is the first to investigate the effects of multi-component exercise training combined with targeted nutritional supplementation on a wide battery of musculoskeletal health outcomes known to be adversely affected by ADT. This provided a comprehensive assessment of the effects of our intervention on a battery of common fracture risk factors. However, there are several limitations. Firstly, due to the lack of a factorial 2x2 study design we cannot address the question of whether the combination of exercise with nutritional supplementation is more effective (additive or synergistic) than either approach alone. Secondly, we did not reach our target sample size which likely limited the statistical power to detect possible between group differences in some bone outcomes, particularly bone structure and strength estimates. Thirdly, intervention adherence was relatively modest and our per protocol analyses were limited by a small number of men who met pre-specified cut points for both

exercise and supplement adherence. Furthermore, we could not access either tumor characteristics or cancer recurrence data, so the intervention's effect on these clinical outcomes could not be evaluated. Additionally, compared to more precise objective physical activity assessment, the subjective physical activity measurement tool used in this study may have limited our ability to capture differences and changes in habitual physical activity throughout the intervention. Finally, volunteer bias may limit the generalisability of the results as it is possible that participants capable of completing the intervention volunteered for the study knowing they could be allocated to a 12-month exercise and nutritional supplementation intervention.

In conclusion, we have demonstrated that a 12-month multi-component exercise program combined with a daily protein, calcium and vitamin D enriched supplement was largely ineffective for improving or maintaining bone density, structure or strength, body composition or muscle function in men with PCa treated with ADT compared to usual care. This is likely related to the modest intervention adherence as there was some evidence that the intervention was effective for improving FN aBMD and total body lean mass among highly adherent participants. Further research is therefore required to identify strategies to promote long-term exercise adherence for this cohort of men.

Acknowledgements

We are grateful to Omniblend (Campbellfield, Victoria, Australia) for providing the whey-protein, calcium and vitamin D enriched powder, Sanofi-Aventis Australia Pty Ltd (Macquarie Park, New South Wales, Australia) for providing the vitamin D supplements (Ostelin) and YMCA Victoria for providing gym memberships for our participants. Gerontology Research Center is a joint effort between the University of Jyväskylä and the University of Tampere. The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of the present study do not constitute endorsement by ACSM.

Funding: The study received in-kind support from YMCA Victoria, Ostelin and Omniblend. Facilities, equipment and internal funding were provided by Deakin University.

Conflicts of interest: Robin M. Daly has received funding from a Primary Growth Partnership grant via the Ministry of Primary Industries in New Zealand with Fonterra Co-operative Group Ltd. Declan G. Murphy has received honoraria for advisory board and speaker duties from Astellas, Janssen, Astra Zeneca, Bayer, Ferring and Ipsen. All other authors declare that they have no conflicts of interest.

Author contributions: Study design: PJO, RMD, PML, SFF. Study conduct: JDV, PJO, NLM, SJF. Data collection: JDV, PJO, NLM, SJF. Data analysis: JDV, TR, PJO. Data interpretation: JDV, RMD. Drafting manuscript: JDV. Revising manuscript content: All. Approving final version of manuscript: All. JDV takes responsibility for the integrity of the data analysis.

REFERENCES

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 2.2020: NCCN; 2020.
2. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. *J Clin Oncol*. 2014;32(4):335-46. doi: 10.1200/JCO.2013.49.5523.
3. Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. *BJU Int*. 2008;102(1):44-7.
4. Owen P, Daly R, Livingston P, Fraser S. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. *Prostate Cancer Prostatic Dis*. 2017;20(2):137-45.
5. Hamilton E, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. *J Clin Endocrinol Metab*. 2010;95(12):E456-E63.
6. Storer TW, Miciek R, Trivison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. *Asian J Androl*. 2012;14(2):204-21.
7. Wallander M, Axelsson KF, Lundh D, Lorentzon M. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO). *Osteoporos Int*. 2019;30(1):115-25.
8. Nguyen C, Lairson DR, Swartz MD, Du XL, Therapy D. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer. *Pharmacotherapy*. 2018;38(10):999-1009.

9. Cormie P, Zopf EM. Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. *Urologic Oncology*. 2020;38(2):62-70. doi: 10.1016/j.urolonc.2018.10.008.
10. Newton RU, Galvão DA, Spry N, et al. Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients. *Med Sci Sports Exerc*. 2019;51(4):607-14. doi: 10.1249/mss.0000000000001831.
11. Uth J, Hornstrup T, Christensen JF, et al. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. *Osteoporos Int*. 2016;27(4):1507-18.
12. Cormie P, Galvão DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. *BJU Int*. 2015;115(2):256-66.
13. Nilsen TS, Raastad T, Skovlund E, et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. *Acta Oncol*. 2015;54(10):1805-13.
14. Taaffe DR, Galvão DA, Spry N, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. *BJU Int*. 2019;123(2):261-9.
15. Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer TM. Skeletal response to resistance and impact training in prostate cancer survivors. *Med Sci Sports Exerc*. 2014;46(8):1482-8. doi: 10.1249/MSS.0000000000000265.
16. Fonseca H, Moreira-Gonçalves D, Coriolano H-JA, Duarte JA. Bone quality: the

determinants of bone strength and fragility. *Sports Med.* 2014;44(1):37-53.

17. Tsang DS, Alibhai SM. Bone health care for patients with prostate cancer receiving androgen deprivation therapy. *Hosp Pract (1995).* 2014;42(2):89-102.

18. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. *Lancet.* 2007;370(9588):657-66.

19. Daly RM, Brown M, Bass S, Kukuljan S, Nowson C. Calcium-and Vitamin D3-Fortified Milk Reduces Bone Loss at Clinically Relevant Skeletal Sites in Older Men: A 2-Year Randomized Controlled Trial. *J Bone Miner Res.* 2006;21(3):397-405.

20. Morley JE, Argiles JM, Evans WJ, et al. Nutritional recommendations for the management of sarcopenia. *J Am Med Dir Assoc.* 2010;11(6):391-6.

21. Antoniak AE, Greig CA. The effect of combined resistance exercise training and vitamin D3 supplementation on musculoskeletal health and function in older adults: a systematic review and meta-analysis. *BMJ Open.* 2017;7(7):e014619. Epub 2017/07/22. doi: 10.1136/bmjopen-2016-014619.

22. Cermak NM, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. *Am J Clin Nutr.* 2012;96(6):1454-64.

23. Owen PJ, Daly RM, Livingston PM, et al. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. *Trials.* 2017;18(1):451.

24. American College of Sports Medicine. ACSM's guidelines for exercise testing and

prescription. 6th ed. Philadelphia (USA): Lippincott Williams & Wilkins; 2010.

25. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. *Osteoporos Int.* 1994;4(6):368-81.
26. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012;9(7):676-82.
27. Doube M, Klosowski MM, Arganda-Carreras I, et al. BoneJ: free and extensible bone image analysis in ImageJ. *Bone.* 2010;47(6):1076-9.
28. Rantalainen T, Nikander R, Heinonen A, Daly R, Sievänen H. An open source approach for regional cortical bone mineral density analysis. *J Musculoskelet Neuronal Interact.* 2011;11(3):243-8.
29. Kontulainen S, Johnston J, Liu D, Leung C, Oxland T, McKay H. Strength indices from pQCT imaging predict up to 85% of variance in bone failure properties at tibial epiphysis and diaphysis. *J Musculoskelet Neuronal Interact.* 2008;8(4):401-9.
30. Laskey MA, de Bono S, Zhu D, et al. Evidence for enhanced characterization of cortical bone using novel pQCT shape software. *J Clin Densitom.* 2010;13(3):247-55.
31. Blew RM, Lee VR, Farr JN, Schiferl DJ, Going SB. Standardizing evaluation of pQCT image quality in the presence of subject movement: qualitative versus quantitative assessment. *Calcif Tissue Int.* 2014;94(2):202-11.
32. Rantalainen T, Chivers P, Beck BR, et al. Please Don't Move—Evaluating Motion Artifact From Peripheral Quantitative Computed Tomography Scans Using Textural Features. *J Clin Densitom.* 2018;21(2):260-8.
33. Rinaldi G, Wisniewski CA, Setty NG, LeBoff MS. Peripheral quantitative computed tomography: optimization of reproducibility measures of bone density, geometry, and strength at

the radius and tibia. *J Clin Densitom.* 2011;14(3):367-73.

34. Frank-Wilson AW, Johnston JD, Olszynski WP, Kontulainen SA. Measurement of muscle and fat in postmenopausal women: precision of previously reported pQCT imaging methods. *Bone.* 2015;75:49-54.

35. Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL. CHAMPS physical activity questionnaire for older adults: outcomes for interventions. *Med Sci Sports Exerc.* 2001(33):1126-41.

36. Gianoudis J, Bailey CA, Ebeling PR, et al. Effects of a targeted multimodal exercise program incorporating high-speed power training on falls and fracture risk factors in older adults: a community-based randomized controlled trial. *J Bone Miner Res.* 2014;29(1):182-91.

37. Cole T. Sympercents: symmetric percentage differences on the 100 loge scale simplify the presentation of log transformed data. *Stat Med.* 2000;19(22):3109-25.

38. Harding AT, Weeks BK, Lambert C, Watson SL, Weis LJ, Beck BR. Effects of supervised high-intensity resistance and impact training or machine-based isometric training on regional bone geometry and strength in middle-aged and older men with low bone mass: The LIFTMOR-M semi-randomised controlled trial. *Bone.* 2020;136:115362. doi: <https://doi.org/10.1016/j.bone.2020.115362>.

39. Kukuljan S, Nowson CA, Sanders KM, et al. Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. *J Clin Endocrinol Metab.* 2011;96(4):955-63.

40. Lanyon L, Skerry T. Perspective: postmenopausal osteoporosis as a failure of bone's adaptation to functional loading: a hypothesis. *J Bone Miner Res.* 2001;16(11):1937-47.

41. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic

exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. *J Clin Oncol.* 2010;28(2):340-7.

42. Wall BA, Galvão DA, Fatehee N, et al. Exercise Improves V̇O₂max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients. *Med Sci Sports Exerc.* 2017;49(8):1503-10.

43. Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer. *Oncol Nurs Forum.* 2015;42(4):348-56.

44. Chen Z, Zhang Y, Lu C, Zeng H, Schumann M, Cheng S. Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: A systematic review and meta-analysis. *Front Physiol.* 2019;10:843.

45. Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. *Med Sci Sports Exerc.* 2011;43(2):249.

46. Holwerda AM, Paulussen KJ, Overkamp M, et al. Dose-dependent increases in whole-body net protein balance and dietary protein-derived amino acid incorporation into myofibrillar protein during recovery from resistance exercise in older men. *J Nutr.* 2019;149(2):221-30.

47. Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein considerations for optimising skeletal muscle mass in healthy young and older adults. *Nutrients.* 2016;8(4):181.

48. Finger D, Goltz FR, Umpierre D, Meyer E, Rosa LHT, Schneider CD. Effects of protein supplementation in older adults undergoing resistance training: a systematic review and meta-analysis. *Sports Med.* 2015;45(2):245-55.

49. Hou L, Lei Y, Li X, et al. Effect of protein supplementation combined with resistance training on muscle mass, strength and function in the elderly: A systematic review and meta-analysis. *J Nutr Health Aging*. 2019;23(5):451-8.
50. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. *Br J Sports Med*. 2018;52(6):376-84.
51. Gielen E, Beckwée D, Delaere A, De Breucker S, Vandewoude M, Bautmans I. Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. *Nutr Rev*. 2021;79(2):121-47.
52. Kiss N, Baguley BJ, Dalla Via J, Fraser SF, Bolam KA, Daly RM. Exercise and Nutritional Approaches to Combat Cancer-Related Bone and Muscle Loss. *Curr Osteoporos Rep*. 2020:1-10.
53. Winters-Stone KM, Dobek JC, Bennett JA, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. *Arch Phys Med Rehabil*. 2015;96(1):7-14.
54. Newton RU, Galvão DA, Spry N, et al. Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer. *Prostate Cancer Prostatic Dis*. 2020;23(3):457-64. Epub 2020/02/06. doi: 10.1038/s41391-019-0200-z.
55. Nabuco HCG, Tomeleri CM, Fernandes RR, et al. Effect of whey protein supplementation combined with resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity: A randomized, double-blind, placebo-controlled trial. *Clin Nutr ESPEN*. 2019;32:88-95. doi:

<https://doi.org/10.1016/j.clnesp.2019.04.007>.

56. Baer DJ, Stote KS, Paul DR, Harris GK, Rumpler WV, Clevidence BA. Whey protein but not soy protein supplementation alters body weight and composition in free-living overweight and obese adults. *J Nutr.* 2011;141(8):1489-94.

ACCEPTED

Figure legends:

Figure 1. Participant flow through the study.

Supplemental digital content:

Dalla Via et al_IMPACT_Supplementary tables_MSSE.docx

ACCEPTED

Figure 1




Table 1. Baseline characteristics of participants

	Ex+Suppl	Control
n	34	36
Age (years)	71.4 ± 5.9	71.1 ± 6.6
Height (cm)	175.3 ± 6.6	175.0 ± 6.4
Weight (kg)	87.6 ± 16.9	89.3 ± 17.6
Body mass index (BMI, kg/m ²)	28.4 ± 4.3	29.2 ± 5.7
Overweight, n (%)	19 (55.9)	18 (50.0)
Obese, n (%)	10 (29.4)	11 (30.6)
Ethnicity, n (%)		
Caucasian	33 (97.1)	35 (97.2)
Asian	0 (0.0)	1 (2.8)
African	1 (2.9)	0 (0.0)
Comorbidities [#] , n (%)	31 (91.2)	31 (86.1)
If yes, total (n)	2.5 ± 1.3	2.8 ± 1.3
Prescription medication, n (%)	27 (79.4)	28 (77.8)
If yes, total (n)	2.7 ± 1.7	4.1 ± 2.5
Physical activity (kJ/d)	3043 ± 1770	2248 ± 1571
Diet		
Energy (kJ/d)	8920 ± 2941	8412 ± 2178
Protein (g/kg/d)	1.12 ± 0.42	1.01 ± 0.28
Carbohydrate (g/d)	219 ± 99	210 ± 76
Fat (g/d)	75 ± 31	79 ± 37
Calcium (mg/d)	821 ± 369	860 ± 384
Serum 25(OH)D (nmol/L)	67.8 ± 21.7	71.9 ± 21.0
Serum IGF-1 (nmol/L)	21.5 ± 6.2	20.4 ± 8.7
Time since PCa diagnosis (months), median (IQR)	34 (12-78)	53 (16-137)
Stage of PCa, n (%)		
Localised/removed	10 (29.4)	10 (27.8)
Advanced	22 (64.7)	23 (63.9)
Unknown	2 (5.9)	3 (8.3)
Prostate specific antigen (PSA, µg/L), median (IQR)	0.38 (0.02, 1.04)	0.17 (0.02, 1.20)
Presence of bone metastasis, n (%)	10 (29.4)	10 (27.8)
ADT duration (months), median (IQR)	8 (4-22)	13 (8-24)
Previous prostatectomy, n (%)	16 (47.1)	18 (50.0)
Previous radiotherapy, n (%)	21 (61.8)	27 (75.0)
Previous chemotherapy, n (%)	5 (14.7)	6 (16.7)
Osteoporosis classification, n (%)		

Normal	15 (44.1)	16 (44.4)
Osteopenia	17 (50.0)	18 (50.0)
Osteoporosis	2 (5.9)	2 (5.6)
Fracture since age 45, n (%)	5 (14.7)	10 (27.8)
Fall in previous 12 months, n (%)	4 (11.8)	7 (19.4)

Data are: mean \pm standard deviation unless stated otherwise. #comorbidities included asthma/respiratory problems, chronic bronchitis, muscle/ligament problems, back pain, angina/stroke/heart condition, diabetes, hypertension and hypercholesterolaemia. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Table 2. Mean lumbar spine, femoral neck and total hip aBMD at baseline, percentage within-group changes from baseline and the net between-group differences for the change from baseline to six and 12 months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value Interaction
	n	Mean ± SD or (95% CI)	P-value	n	Mean ± SD or (95% CI)	P-value		
Lumbar spine								
Baseline, g/cm ²	34	1.254 ± 0.218		36	1.261 ± 0.198			
% Δ 6 months	32	0.31 (-1.08, 1.70)	0.667	30	0.13 (-0.71, 0.98)	0.955	0.18 (-1.44, 1.80)	0.751
% Δ 12 months	30	-0.69 (-2.40, 1.03)	0.272	29	-0.61 (-2.01, 0.79)	0.213	-0.08 (-2.25, 2.09)	0.869
Femoral neck								
Baseline, g/cm ²	34	0.971 ± 0.134		36	0.946 ± 0.129			
% Δ 6 months	33	-0.55 (-1.34, 0.25)	0.158	30	-0.41 (-1.46, 0.64)	0.406	-0.14 (-1.41, 1.14)	0.670
% Δ 12 months	30	-1.20 (-2.39, -0.02)	0.022	29	-1.78 (-2.86, -0.71)	<0.001	0.58 (-0.99, 2.15)	0.349
Total hip								
Baseline, g/cm ²	34	1.051 ± 0.131		35	1.005 ± 0.152			
% Δ 6 months	33	-0.83 (-1.64, -0.03)	0.024	30	-0.56 (-1.18, 0.06)	0.158	-0.28 (-1.29, 0.74)	0.431
% Δ 12 months	30	-1.91 (-2.71, -1.11)	<0.001	29	-1.09 (-1.89, -0.30)	0.001	-0.82 (-1.92, 0.29)	0.128

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). Ex+Suppl, multi-component

exercise program combined with protein, calcium and vitamin D supplementation; aBMD, areal bone mineral density.

Table 3. Mean vBMD, bone structure and strength at the distal and proximal tibia and radius at baseline, percentage within-group changes from baseline and the net between-group differences for the change from baseline to six and 12 months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value Interaction
	n	Mean ± SD or (95% CI)	P-value	n	Mean ± SD or (95% CI)	P-value		
Distal tibia (4%)								
Trabecular vBMD								
Baseline, mg/cm ³	33	243 ± 29		33	238 ± 33			
% Δ 6 months	31	-0.25 (-0.82, 0.33)	0.406	28	-0.50 (-1.04, 0.04)	0.102	0.25 (-0.52, 1.03)	0.562
% Δ 12 months	28	-0.55 (-1.24, 0.15)	0.067	26	-0.42 (-1.26, 0.43)	0.135	-0.13 (-1.19, 0.93)	0.815
BSI								
Baseline, mg ² /mm ⁴	33	1.256 ± 0.246		33	1.168 ± 0.279			
% Δ 6 months ^b	31	-2.72 (-3.49, -1.94)	<0.001 ^a	28	-2.76 (-3.64, -1.89)	<0.001 ^a	0.05 (-1.09, 1.19)	0.956 ^a
% Δ 12 months ^b	28	-4.50 (-5.61, -3.39)	<0.001 ^a	26	-3.79 (-5.06, -2.51)	<0.001 ^a	-0.72 (-2.36, 0.93)	0.416 ^a
Distal radius (4%)								
Trabecular vBMD								
Baseline, mg/cm ³	33	184 ± 34		35	191 ± 45			
% Δ 6 months ^b	32	-1.21 (-2.76, 0.33)	0.155 ^a	27	-2.57 (-4.40, -0.73)	0.005 ^a	1.35 (-0.97, 3.68)	0.288 ^a
% Δ 12 months ^b	27	-2.70 (-5.05, -0.34)	0.011 ^a	24	-2.92 (-5.41, -0.43)	0.001 ^a	0.22 (-3.12, 3.56)	0.524 ^a
BSI								
Baseline, mg ² /mm ⁴	33	0.461 ± 0.109		35	0.445 ± 0.117			
% Δ 6 months	32	-6.23 (-8.87, -3.59)	<0.001	27	-6.58 (-9.46, -3.70)	<0.001	0.35 (-3.47, 4.17)	0.859
% Δ 12 months	27	-10.60 (-14.28, -6.91)	<0.001	24	-9.19 (-12.51, -5.86)	<0.001	-1.41 (-6.29, 3.47)	0.387
Proximal tibia (66%)								
Total area								

Baseline, mm ²	34	858 ± 113		32	824 ± 112			
% Δ 6 months	32	-0.38 (-0.99, 0.23)	0.145	28	-0.58 (-1.18, 0.02)	0.036	0.20 (-0.64, 1.04)	0.730
% Δ 12 months	29	0.01 (-0.71, 0.72)	0.867	26	-0.37 (-0.88, 0.14)	0.161	0.38 (-0.50, 1.26)	0.417
Cortical area								
Baseline, mm ²	34	393 ± 38		32	397 ± 54			
% Δ 6 months	32	-0.31 (-0.86, 0.23)	0.284	28	-0.98 (-1.51, -0.44)	0.002	0.66 (-0.09, 1.41)	0.151
% Δ 12 months	29	-1.49 (-2.23, -0.74)	<0.001	26	-1.87 (-2.62, -1.13)	<0.001	0.39 (-0.64, 1.42)	0.513
Medullary area								
Baseline, mm ²	34	465 ± 102		32	426 ± 121			
% Δ 6 months	32	-0.43 (-1.45, 0.59)	0.372	28	-0.18 (-1.20, 0.85)	0.583	-0.25 (-1.67, 1.17)	0.718
% Δ 12 months	29	1.40 (-0.07, 2.88)	0.056	26	1.06 (0.28, 1.84)	0.098	0.35 (-1.34, 2.03)	0.620
Cortical vBMD								
Baseline, mg/cm ³	34	992 ± 54		32	1004 ± 44			
% Δ 6 months	32	-0.69 (-1.40, 0.02)	0.025	28	-1.03 (-1.67, -0.38)	<0.001	0.33 (-0.62, 1.29)	0.462
% Δ 12 months	29	-1.18 (-1.83, -0.53)	<0.001	26	-1.18 (-1.94, -0.41)	<0.001	0.001 (-0.97, 0.97)	0.853
I_{polar}								
Baseline, mg/cm	34	9267 ± 1879		32	8923 ± 1744			
% Δ 6 months	32	-1.40 (-2.14, -0.66)	0.001	28	-2.17 (-3.10, -1.24)	<0.001	0.77 (-0.38, 1.92)	0.273
% Δ 12 months	29	-2.12 (-3.13, -1.12)	<0.001	26	-2.56 (-3.78, -1.34)	<0.001	0.43 (-1.10, 1.97)	0.707
Proximal radius (66%)								
Total area								
Baseline, mm ²	32	189 ± 34		32	182 ± 25			
% Δ 6 months	31	0.16 (-1.31, 1.63)	0.981	27	1.20 (-0.64, 3.05)	0.111	-1.05 (-3.32, 1.23)	0.239
% Δ 12 months	27	0.17 (-1.21, 1.55)	0.887	24	0.69 (-0.49, 1.87)	0.416	-0.52 (-2.31, 1.27)	0.618
Cortical area								
Baseline, mm ²	32	109 ± 12		32	110 ± 14			

% Δ 6 months	31	-1.24 (-2.61, 0.13)	0.119	27	-0.94 (-2.15, 0.26)	0.129	-0.30 (-2.11, 1.51)	0.777
% Δ 12 months	27	-1.72 (-3.44, -0.003)	0.012	24	-2.31 (-3.59, -1.03)	<0.001	0.59 (-1.55, 2.73)	0.857
Medullary area								
Baseline, mm ²	32	80 ± 31		32	72 ± 20			
% Δ 6 months ^b	31	2.07 (-0.88, 5.02)	0.154 ^a	27	4.33 (0.82, 7.83)	0.002^a	-2.26 (-6.71, 2.19)	0.242 ^a
% Δ 12 months ^b	27	3.08 (0.13, 6.02)	0.015^a	24	6.08 (3.68, 8.47)	<0.001^a	-3.00 (-6.77, 0.77)	0.269 ^a
Cortical vBMD								
Baseline, mg/cm ³	32	1010 ± 76		32	1027 ± 50			
% Δ 6 months	31	-0.16 (-0.91, 0.59)	0.792	27	-1.59 (-2.50, -0.68)	0.001	1.43 (0.29, 2.57)	0.035
% Δ 12 months	27	-1.86 (-3.12, -0.60)	0.001	24	-1.82 (-2.78, -0.86)	<0.001	-0.03 (-1.61, 1.53)	0.859
I_{polar}								
Baseline, mg/cm	32	444 ± 121		32	433 ± 103			
% Δ 6 months	31	-1.32 (-3.44, 0.80)	0.187	27	-1.10 (-3.71, 1.52)	0.479	-0.22 (-3.48, 3.03)	0.638
% Δ 12 months	27	-3.03 (-5.69, -0.37)	0.007	24	-1.99 (-4.16, 0.18)	0.157	-1.04 (-4.43, 2.36)	0.325

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model, ^b Percent change calculated from absolute change in natural log transformed data. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation; vBMD, volumetric bone mineral density; BSI, bone strength index; I_{polar}; density-weighted polar cross-sectional moment of inertia.

Table 4. Mean total and regional body composition at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to six and 12 months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value Interaction
	n	Mean ± SD or (95% CI)	P-value	n	Mean ± SD or (95% CI)	P-value		

Weight								
Baseline, kg	34	87.6 ± 16.9		36	89.3 ± 17.6			
Δ 6 months	33	0.21 (-1.02, 1.43)	0.740	31	0.36 (-0.62, 1.33)	0.505	-0.15 (-1.69, 1.40)	0.891
Δ 12 months	31	0.87 (-0.74, 2.48)	0.165	29	-0.09 (-1.38, 1.21)	0.886	0.96 (-1.08, 3.00)	0.238
Total body lean mass								
Baseline, kg	33	53.0 ± 6.1		36	54.5 ± 6.8			
Δ 6 months	32	0.07 (-0.56, 0.70)	0.793	30	-0.18 (-0.64, 0.28)	0.504	0.25 (-0.52, 1.02)	0.509
Δ 12 months	29	0.17 (-0.40, 0.74)	0.388	29	-0.31 (-1.01, 0.39)	0.222	0.48 (-0.40, 1.36)	0.142
Appendicular lean mass								
Baseline, kg	33	24.4 ± 3.3		36	25.0 ± 3.8			
Δ 6 months	32	0.08 (-0.35, 0.51)	0.655	30	-0.02 (-0.26, 0.22)	0.875	0.10 (-0.39, 0.59)	0.650
Δ 12 months	29	0.01 (-0.37, 0.40)	0.832	29	-0.30 (-0.65, 0.06)	0.033	0.31 (-0.21, 0.82)	0.150
Total body fat mass								
Baseline, kg	33	29.5 ± 9.1		36	31.5 ± 12.3			
Δ 6 months	32	0.26 (-0.60, 1.11)	0.548	30	0.59 (-0.34, 1.53)	0.221	-0.34 (-1.58, 0.90)	0.642
Δ 12 months	29	1.05 (-0.09, 2.18)	0.020	29	0.19 (-0.91, 1.28)	0.591	0.86 (-0.68, 2.40)	0.213
Proximal tibia (66%)								
Muscle CSA								
Baseline, mm ²	33	76.52 ± 10.79		33	74.24 ± 12.63			
% Δ 6 months	31	-0.74 (-2.26, 0.77)	0.065	28	-0.93 (-2.31, 0.45)	0.160	0.19 (-1.83, 2.21)	0.567
% Δ 12 months	28	-1.68 (-3.49, 0.13)	0.022	26	-1.48 (-2.96, -0.00)	0.027	-0.20 (-2.51, 2.10)	0.644

Subcutaneous fat CSA

Baseline, mm ²	33	20.91 ± 12.11		33	23.29 ± 10.11			
% Δ 6 months	32	7.82 (2.72, 12.92)	0.055	28	3.23 (-0.09, 6.56)	0.144	4.58 (-1.57, 10.74)	0.513
% Δ 12 months	28	14.54 (6.83, 22.26)	<0.001	26	4.76 (0.03, 9.49)	0.006	9.78 (0.78, 18.79)	0.030

Muscle density

Baseline, mg/cm ³	33	74.39 ± 3.14		33	74.03 ± 3.53			
% Δ 6 months	32	0.05 (-0.69, 0.79)	0.852	28	0.58 (-0.04, 1.20)	0.120	-0.53 (-1.50, 0.43)	0.336
% Δ 12 months	28	-1.19 (-2.08, -0.30)	0.002	26	-0.32 (-1.10, 0.45)	0.346	-0.87 (-2.03, 0.29)	0.108

Proximal radius (66%)**Muscle CSA**

Baseline, mm ²	32	38.95 ± 5.16		31	38.57 ± 6.52			
% Δ 6 months ^b	32	-0.85 (-2.47, 0.76)	0.304 ^a	26	0.29 (-1.33, 1.90)	0.911 ^a	-1.14 (-3.40, 1.12)	0.475 ^a
% Δ 12 months ^b	28	-1.98 (-4.23, 0.27)	0.058 ^a	26	-0.36 (-3.38, 2.66)	0.783 ^a	-1.62 (-5.26, 2.02)	0.337 ^a

Subcutaneous fat CSA

Baseline, mm ²	32	11.53 ± 4.64		31	12.98 ± 6.61			
% Δ 6 months ^b	32	7.30 (3.47, 11.13)	<0.001^a	26	4.75 (0.32, 9.18)	0.038^a	2.55 (-3.15, 8.25)	0.380 ^a
% Δ 12 months ^b	28	12.80 (7.06, 18.53)	<0.001^a	26	3.76 (-1.58, 9.11)	0.061 ^a	9.03 (1.35, 16.72)	0.004^a

Muscle density

Baseline, mg/cm ³	32	77.96 ± 2.57		31	77.00 ± 2.48			
% Δ 6 months	32	-0.72 (-1.44, -0.001)	0.047	26	-0.05 (-0.93, 0.83)	0.990	-0.67 (-1.77, 0.43)	0.237
% Δ 12 months	28	-1.23 (-2.17, -0.30)	0.003	26	0.49 (-0.83, 1.80)	0.405	-1.72 (-3.28, -0.16)	0.012

Baseline values represent means \pm SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model. ^b Percent change calculated from absolute change in natural log transformed data. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Table 5. Mean muscle strength and physical function results at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to six and 12 months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean ± SD or (95% CI)	P-value	n	Mean ± SD or (95% CI)	P-value		
Muscle strength								
Leg press 3RM								
Baseline, kg	31	142.7 ± 39.8		29	136.4 ± 54.0			
Δ 6 months	29	18.4 (7.9, 28.8)	0.001	23	3.8 (-2.1, 9.7)	0.291	14.6 (2.0, 27.2)	0.048
Δ 12 months	27	26.8 (12.6, 40.9)	<0.001	20	7.5 (0.0, 15.0)	0.036	19.3 (1.9, 36.6)	0.007
Chest press 3RM								
Baseline, kg	29	37.5 ± 10.1		25	38.9 ± 10.6			
Δ 6 months	27	2.4 (-0.6, 5.3)	0.044	22	-1.3 (-3.0, 0.5)	0.189	3.6 (0.1, 7.2)	0.024
Δ 12 months	23	1.3 (-1.5, 4.0)	0.083	18	0.1 (-2.5, 2.7)	0.942	1.2 (-2.6, 4.9)	0.209
Seated row 3RM								
Baseline, kg	28	49.1 ± 12.3		26	48.3 ± 10.3			
Δ 6 months	28	1.8 (-1.8, 5.5)	0.183	20	0.5 (-1.6, 2.5)	0.607	1.4 (-3.2, 5.9)	0.470
Δ 12 months	25	1.5 (-2.0, 5.0)	0.175	17	0.8 (-1.9, 3.5)	0.626	0.7 (-4.0, 5.4)	0.465
Grip strength								
Baseline, kg	31	38.2 ± 6.0		32	37.7 ± 7.0			
Δ 6 months	31	-0.8 (-2.0, 0.3)	0.226	27	-0.1 (-1.5, 1.7)	0.866	-1.0 (-2.9, 0.9)	0.349
Δ 12 months	30	-1.8 (-3.4, -0.3)	0.007	26	-0.4 (-2.2, 1.4)	0.482	-1.4 (-3.7, 0.9)	0.202
Physical function								
30-second sit-to-stand								
Baseline, repetitions	34	12.8 ± 4.2		36	12.6 ± 3.8			

Δ 6 months	33	0.5 (-0.8, 1.8)	0.428	31	-0.8 (-1.7, 0.2)	0.127	1.3 (-0.3, 2.8)	0.142
Δ 12 months	31	0.0 (-1.3, 1.2)	0.920	28	-1.4 (-2.4, -0.4)	0.005	1.4 (-0.3, 3.0)	0.137
Timed up-and-go with cognitive task								
Baseline, seconds	34	10.80 ± 3.16		36	11.83 ± 4.48			
Δ 6 months	33	-0.20 (-1.30, 0.91)	0.827 ^a	31	-0.27 (-1.78, 1.24)	0.654 ^a	0.07 (-1.74, 1.89)	0.859 ^a
Δ 12 months	31	0.52 (-0.83, 1.87)	0.445 ^a	29	-0.55 (-2.17, 1.07)	0.742 ^a	1.07 (-0.98, 3.13)	0.447 ^a
Four square step test								
Baseline, seconds	34	9.73 ± 1.93		36	9.62 ± 2.25			
Δ 6 months	33	-1.07 (-1.60, -0.53)	<0.001	31	-0.08 (-0.54, 0.37)	0.684	-0.98 (-1.67, -0.29)	0.003
Δ 12 months	31	-0.80 (-1.38, -0.22)	0.002	29	-0.03 (-0.54, 0.47)	0.918	-0.77 (-1.53, -0.01)	0.014
Gait speed								
Baseline, m/sec	31	1.42 ± 0.20		33	1.43 ± 0.22			
Δ 6 months	31	0.00 (-0.04, 0.04)	0.947 ^a	28	-0.02 (-0.07, 0.03)	0.671 ^a	0.02 (-0.05, 0.08)	0.718 ^a
Δ 12 months	30	-0.01 (-0.06, 0.04)	0.588 ^a	27	-0.01 (-0.07, 0.05)	0.776 ^a	0.00 (-0.08, 0.08)	0.882 ^a
400m walk								
Baseline, seconds	34	283.7 ± 39.2		33	290.9 ± 37.7			
Δ 6 months	33	8.4 (-3.4, 20.3)	0.180 ^a	30	9.7 (-0.6, 20.1)	0.060 ^a	-1.3 (-16.8, 14.3)	0.968 ^a
Δ 12 months	29	11.3 (-6.8, 29.4)	0.133 ^a	26	12.1 (0.1, 24.2)	0.049^a	-0.8 (-22.6, 21.0)	0.935 ^a
Berg Balance Scale								
Baseline, score	33	55.2 ± 1.3		36	54.3 ± 2.6			
Δ 6 months	32	-0.1 (-0.6, 0.3)	0.533	31	-0.4 (-1.1, 0.4)	0.359	0.3 (-0.6, 1.1)	0.622
Δ 12 months	30	-0.1 (-0.6, 0.3)	0.692	29	-0.03 (-0.5, 0.4)	0.966	-0.1 (-0.7, 0.5)	0.877

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation; 3RM, three repetition maximum.

Supplementary Table 1. Mean physical activity levels and dietary energy, carbohydrate, protein, fat, calcium and alcohol intake at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
Physical activity								
Baseline, kJ/d	34	3043 \pm 1770		36	2248 \pm 1571			
Δ 6 months	32	588 (-280, 1456)	0.182 ^a	32	-90 (-637, 456)	0.938 ^a	678 (-343, 1699)	0.330 ^a
Δ 12 months	32	-69 (-722, 583)	0.836 ^a	29	453 (70, 835)	0.040^a	-522 (-1283, 239)	0.133 ^a
Dietary intake								
Energy								
Baseline, kJ/d	30	8920 \pm 2941		30	8412 \pm 2178			
Δ 6 months	30	200 (-632, 1032)	0.831	25	442 (-490, 1373)	0.641	-242 (-1459, 975)	0.766
Δ 12 months	29	-628 (-1619, 364)	0.225	26	155 (-793, 1103)	0.908	-783 (-2130, 565)	0.390
Carbohydrate								
Baseline, g/d	30	219 \pm 99		30	210 \pm 76			
Δ 6 months	30	-1 (-28, 26)	0.962	25	17 (-13, 47)	0.615	-18 (-57, 22)	0.622
Δ 12 months	29	-24 (-53, 6)	0.088	26	5 (-31, 41)	0.835	-29 (-74, 16)	0.312
Protein								
Baseline, g/kg/d	30	1.12 \pm 0.42		30	1.01 \pm 0.28			
Δ 6 months	30	0.07 (-0.09, 0.22)	0.703	25	0.01 (-0.11, 0.13)	0.758	0.06 (-0.14, 0.25)	0.905
Δ 12 months	29	0.02 (-0.15, 0.20)	0.369	26	-0.01 (-0.12, 0.11)	0.800	0.03 (-0.18, 0.24)	0.570
Fat								
Baseline, g/d	30	75.2 \pm 31.4		30	79.3 \pm 36.7			
Δ 6 months	30	7.4 (-4.2, 19.1)	0.380 ^a	25	2.1 (-14.5, 18.7)	0.596 ^a	5.3 (-14.0, 24.6)	0.833 ^a
Δ 12 months	29	-5.5 (-20.1, 9.2)	0.354 ^a	26	1.8 (-12.5, 16.2)	0.801 ^a	-7.3 (-27.4, 12.8)	0.404 ^a
Saturated fat								

Baseline, g/d	30	28.5 ± 13.5		30	27.7 ± 13.0			
Δ 6 months	30	4.9 (-0.7, 10.4)	0.099 ^a	25	-0.6 (-6.4, 5.1)	0.925 ^a	5.5 (-2.4, 13.3)	0.317 ^a
Δ 12 months	29	-0.3 (-5.6, 5.1)	1.000 ^a	26	2.8 (-3.1, 8.7)	0.455 ^a	-3.1 (-10.8, 4.7)	0.465 ^a
Calcium								
Baseline, mg/d	30	821 ± 369		30	860 ± 384			
Δ 6 months	30	134 (-19, 288)	0.091 ^a	25	-77 (-232, 78)	0.248 ^a	211 (-4, 426)	0.052 ^a
Δ 12 months	29	-6 (-160, 148)	0.806 ^a	26	-4 (-209, 202)	0.612 ^a	-3 (-250, 245)	0.828 ^a
Alcohol								
Baseline, g/d	30	19.7 ± 23.3		30	7.0 ± 11.3			
Δ 6 months	30	-5.8 (-11.9, 0.2)	0.045	25	1.4 (-2.6, 5.3)	0.688	-7.2 (-14.6, 0.2)	0.058
Δ 12 months	29	-3.6 (-11.7, 4.5)	0.190	26	-0.4 (-4.4, 3.7)	0.814	-3.3 (-12.4, 5.9)	0.324
% Energy from carbohydrate								
Baseline	30	39.29 ± 7.46		30	40.81 ± 11.82			
Δ 6 months	30	-0.29 (-3.99, 3.41)	0.821	25	-0.11 (-4.68, 4.46)	0.817	-0.18 (-5.86, 5.49)	0.736
Δ 12 months	29	-0.01 (-4.38, 4.36)	0.875	26	0.03 (-4.36, 4.41)	0.794	-0.04 (-6.10, 6.03)	0.930
% Energy from protein								
Baseline	30	18.61 ± 4.96		30	18.71 ± 5.99			
Δ 6 months	30	1.27 (-1.31, 3.86)	0.408 ^a	25	-0.71 (-2.99, 1.58)	0.676 ^a	1.98 (-1.46, 5.42)	0.418 ^a
Δ 12 months	29	3.16 (0.16, 6.16)	0.006^a	26	-0.45 (-3.12, 2.22)	0.911 ^a	3.61 (-0.35, 7.57)	0.068 ^a
% Energy from fat								
Baseline	30	31.51 ± 8.76		30	34.40 ± 10.47			
Δ 6 months	30	1.80 (-1.34, 4.93)	0.546	25	0.28 (-4.68, 5.25)	0.590	1.51 (-4.02, 7.05)	0.973
Δ 12 months	29	-1.14 (-5.17, 2.90)	0.510	26	0.94 (-3.35, 5.24)	0.553	-2.08 (-7.84, 3.68)	0.387

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Supplementary Table 2. Mean 25-hydroxyvitamin D and insulin-like growth factor-1 (IGF-1) at baseline, within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
25-hydroxyvitamin D								
Baseline, nmol/L	34	67.8 \pm 21.7		35	71.9 \pm 21.0			
Δ 6 months	32	20.4 (14.4, 26.5)	<0.001	31	8.0 (3.4, 12.7)	<0.001	12.4 (8.9, 19.9)	0.001
Δ 12 months	31	17.0 (10.6, 23.4)	<0.001	29	11.5 (6.3, 16.7)	<0.001	5.5 (-2.6, 13.6)	0.148
IGF-1								
Baseline, nmol/L	34	21.5 \pm 6.2		35	20.4 \pm 8.7			
Δ 6 months	32	1.2 (0.02, 2.3)	0.080	31	-0.3 (-1.8, 1.1)	0.744	1.5 (-0.3, 3.3)	0.161
Δ 12 months	31	0.1 (-1.3, 1.5)	0.995	29	-0.8 (-2.7, 1.1)	0.259	0.9 (-1.4, 3.2)	0.395

Baseline values represent means \pm SD and change values represent means with 95% confidence intervals (CI). Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Supplementary Table 3. Median prostate specific antigen (PSA) and high sensitivity C-reactive protein (hs-CRP) levels in each group at baseline, 6- and 12-months.

	Ex+Suppl		Control	
	n	Median (IQR)	n	Median (IQR)
PSA, µg/L				
Baseline	34	0.38 (0.02, 1.04)	35	0.17 (0.02, 1.20)
6 months	32	0.24 (0.01, 1.57)	31	0.10 (0.01, 0.84)
12 months	31	0.35 (0.01, 2.99)	29	0.56 (0.01, 1.58)
hs-CRP, mg/L				
Baseline	34	1.5 (0.7, 3.3)	35	1.2 (0.6, 2.3)
6 months	32	1.2 (0.7, 3.5)	31	1.3 (0.4, 2.9)
12 months	31	1.3 (0.7, 2.4)	29	1.0 (0.6, 1.3)

IQR, interquartile range; Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Supplementary Table 4. Mean DXA assessed regional lean and fat mass at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value Interaction
	n	Mean ± SD or (95% CI)	P-value	n	Mean ± SD or (95% CI)	P-value		
Arm lean mass								
Baseline, kg	33	6.21 ± 1.02		36	6.23 ± 1.12			
Δ 6 months	32	-0.04 (-0.14, 0.06)	0.443	30	-0.03 (-0.13, 0.06)	0.626	-0.01 (-0.14, 0.13)	0.930
Δ 12 months	29	-0.03 (-0.15, 0.10)	0.796	29	-0.07 (-0.24, 0.10)	0.333	0.04 (-0.17, 0.24)	0.546
Leg lean mass								
Baseline, kg	33	18.19 ± 2.39		36	18.81 ± 2.82			
Δ 6 months	32	0.12 (-0.25, 0.49)	0.424	30	0.01 (-0.20, 0.23)	0.925	0.11 (-0.32, 0.53)	0.545
Δ 12 months	29	0.04 (-0.27, 0.34)	0.722	29	-0.23 (-0.49, 0.03)	0.028	0.27 (-0.13, 0.66)	0.126
Trunk lean mass								
Baseline, kg	33	25.35 ± 3.03		36	26.00 ± 3.16			
Δ 6 months	32	0.03 (-0.31, 0.37)	0.871	30	-0.12 (-0.48, 0.24)	0.575	0.15 (-0.33, 0.64)	0.591
Δ 12 months	29	0.15 (-0.21, 0.52)	0.243	29	-0.002 (-0.50, 0.49)	0.976	0.16 (-0.45, 0.76)	0.424
Arm fat mass								
Baseline, kg	33	2.92 ± 0.93		36	3.20 ± 1.31			
Δ 6 months	32	0.08 (-0.02, 0.17)	0.118	30	0.05 (-0.04, 0.14)	0.348	0.03 (-0.10, 0.16)	0.622
Δ 12 months	29	0.11 (-0.02, 0.24)	0.027	29	0.02 (-0.09, 0.12)	0.604	0.09 (-0.08, 0.25)	0.205
Leg fat mass								
Baseline, kg	33	8.03 ± 2.47		36	9.26 ± 4.08			
Δ 6 months	32	0.33 (0.08, 0.57)	0.008^a	30	0.30 (0.01, 0.60)	0.023^a	0.02 (-0.36, 0.40)	0.503 ^a
Δ 12 months	29	0.51 (0.19, 0.83)	<0.001^a	29	0.17 (-0.08, 0.43)	0.105 ^a	0.34 (-0.06, 0.74)	0.018^a

Trunk fat mass

Baseline, kg	33	17.56 ± 6.13		36	18.03 ± 7.76			
Δ 6 months	32	-0.13 (-0.75, 0.49)	0.658	30	0.25 (-0.40, 0.90)	0.509	-0.38 (-1.26, 0.50)	0.439
Δ 12 months	29	0.42 (-0.37, 1.22)	0.193	29	-0.01 (-0.83, 0.82)	0.960	0.43 (-0.69, 1.55)	0.381

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Supplementary Table 5. Mean lumbar spine, femoral neck and total hip aBMD at baseline, percentage within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months for participants with exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
Lumbar spine								
Baseline, g/cm ²	11	1.317 \pm 0.246		36	1.261 \pm 0.198			
% Δ 6 months	11	-0.01 (-2.82, 2.80)	0.874	30	0.13 (-0.71, 0.98)	0.955	-0.14 (-2.19, 1.91)	0.835
% Δ 12 months	11	-1.27 (-4.75, 2.22)	0.222	29	-0.61 (-2.01, 0.79)	0.213	-0.66 (-3.61, 2.30)	0.358
Femoral neck								
Baseline, g/cm ²	11	0.932 \pm 0.122		36	0.946 \pm 0.129			
% Δ 6 months	11	-0.33 (-1.65, 0.99)	0.353	30	-0.41 (-1.46, 0.64)	0.406	0.08 (-1.79, 1.95)	0.941
% Δ 12 months	11	0.16 (-1.18, 1.49)	0.898	29	-1.78 (-2.86, -0.71)	<0.001	1.94 (0.06, 3.82)	0.026
Total hip								
Baseline, g/cm ²	11	1.036 \pm 0.116		35	1.005 \pm 0.152			
% Δ 6 months	11	-0.65 (-1.90, 0.60)	0.172	30	-0.56 (-1.18, 0.06)	0.158	-0.09 (-1.31, 1.13)	0.693
% Δ 12 months	11	-0.91 (-2.36, 0.55)	0.063	29	-1.09 (-1.89, -0.30)	0.001	0.19 (-1.32, 1.70)	0.846

Baseline values represent means \pm SD and change values represent means with 95% confidence intervals (CI). Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation; aBMD, areal bone mineral density.

Supplementary Table 6. Mean vBMD, bone structure and strength at the distal and proximal tibia and radius at baseline, percentage within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months for participants with exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
Distal tibia (4%)								
Trabecular vBMD								
Baseline, mg/cm ³	11	245 \pm 35		33	238 \pm 33			
% Δ 6 months	11	0.45 (-0.39, 1.29)	0.390	28	-0.50 (-1.04, 0.04)	0.102	0.95 (-0.03, 1.92)	0.111
% Δ 12 months	11	0.07 (-1.10, 1.24)	0.935	26	-0.42 (-1.26, 0.43)	0.135	0.49 (-0.97, 1.94)	0.456
BSI								
Baseline, mg ² /mm ⁴	11	1.276 \pm 0.279		33	1.168 \pm 0.279			
% Δ 6 months ^b	11	-2.26 (-3.21, -1.31)	<0.001^a	28	-2.76 (-3.64, -1.89)	<0.001^a	0.51 (-0.98, 1.99)	0.529 ^a
% Δ 12 months ^b	11	-3.77 (-5.09, -2.45)	<0.001^a	26	-3.79 (-5.06, -2.51)	<0.001^a	0.01 (-2.08, 2.11)	0.873 ^a
Distal radius (4%)								
Trabecular vBMD								
Baseline, mg/cm ³	11	181 \pm 26		35	191 \pm 45			
% Δ 6 months ^b	11	-2.29 (-5.69, 1.10)	0.164 ^a	27	-2.57 (-4.40, -0.73)	0.005^a	0.27 (-3.18, 3.72)	0.888 ^a
% Δ 12 months ^b	9	-0.80 (-6.02, 4.43)	0.715 ^a	24	-2.92 (-5.41, -0.43)	0.001^a	2.12 (-2.77, 7.02)	0.188 ^a
BSI								
Baseline, mg ² /mm ⁴	11	0.455 \pm 0.099		35	0.445 \pm 0.117			
% Δ 6 months	11	-6.44 (-10.98, -1.90)	0.002	27	-6.58 (-9.46, -3.70)	<0.001	0.15 (-5.04, 5.33)	0.759
% Δ 12 months	9	-10.19 (-16.31, -4.07)	<0.001	24	-9.19 (-12.51, -5.86)	<0.001	-1.00 (-7.29, 5.29)	0.651
Proximal tibia (66%)								

Total area								
Baseline, mm ²	11	863 ± 99		32	824 ± 112			
% Δ 6 months	11	-0.73 (-1.56, 0.10)	0.107	28	-0.58 (-1.18, 0.02)	0.036	-0.15 (-1.20, 0.91)	0.738
% Δ 12 months	11	-0.62 (-1.99, 0.76)	0.127	26	-0.37 (-0.88, 0.14)	0.161	-0.25 (-1.36, 0.87)	0.549
Cortical area								
Baseline, mm ²	11	407 ± 27		32	397 ± 54			
% Δ 6 months	11	-0.89 (-1.75, -0.04)	0.085	28	-0.98 (-1.51, -0.44)	0.002	0.08 (-0.88, 1.05)	0.971
% Δ 12 months	11	-1.22 (-2.52, 0.08)	0.021	26	-1.87 (-2.62, -1.13)	<0.001	0.65 (-0.71, 2.02)	0.398
Medullary area								
Baseline, mm ²	11	456 ± 94		32	426 ± 121			
% Δ 6 months	11	-0.56 (-1.62, 0.50)	0.502	28	-0.18 (-1.20, 0.85)	0.583	-0.39 (-2.12, 1.34)	0.706
% Δ 12 months	11	0.05 (-2.75, 2.84)	0.781	26	1.06 (0.28, 1.84)	0.098	-1.01 (-3.03, 1.00)	0.268
Cortical vBMD								
Baseline, mg/cm ³	11	1008 ± 37		32	1004 ± 44			
% Δ 6 months	11	-0.67 (-1.27, -0.07)	0.173	28	-1.03 (-1.67, -0.38)	<0.001	0.35 (-0.73, 1.44)	0.528
% Δ 12 months	11	-1.43 (-2.62, -0.23)	0.003	26	-1.18 (-1.94, -0.41)	<0.001	-0.25 (-1.61, 1.11)	0.699
I_{polar}								
Baseline, mg/cm	11	9528 ± 1525		32	8923 ± 1744			
% Δ 6 months	11	-1.90 (-3.09, -0.71)	<0.001	28	-2.17 (-3.10, -1.24)	<0.001	0.27 (-1.35, 1.89)	0.898
% Δ 12 months	11	-2.66 (-4.03, -1.30)	<0.001	26	-2.56 (-3.78, -1.34)	<0.001	-0.11 (-2.14, 1.92)	0.588
Proximal radius (66%)								
Total area								
Baseline, mm ²	11	195 ± 29		32	182 ± 25			
% Δ 6 months	11	-1.10 (-3.17, 0.97)	0.271	27	1.20 (-0.64, 3.05)	0.111	-2.30 (-5.41, 0.80)	0.075
% Δ 12 months	11	-0.12 (-2.82, 2.59)	0.841	24	0.69 (-0.49, 1.87)	0.416	-0.81 (-3.19, 1.58)	0.536
Cortical area								
Baseline, mm ²	11	109 ± 11		32	110 ± 14			

% Δ 6 months	11	-1.97 (-3.62, -0.32)	0.085	27	-0.94 (-2.15, 0.26)	0.129	-1.03 (-3.13, 1.07)	0.327
% Δ 12 months	11	-1.15 (-4.52, 2.21)	0.302	24	-2.31 (-3.59, -1.03)	<0.001	1.16 (-1.62, 3.93)	0.442
Medullary area								
Baseline, mm ²	11	85 ± 23		32	72 ± 20			
% Δ 6 months ^b	11	-0.09 (-4.99, 4.81)	0.957 ^a	27	4.33 (0.82, 7.83)	0.002^a	-4.42 (-10.55, 1.72)	0.090 ^a
% Δ 12 months ^b	11	1.93 (-3.84, 7.71)	0.387 ^a	24	6.08 (3.68, 8.47)	<0.001^a	-4.14 (-9.10, 0.82)	0.139 ^a
Cortical vBMD								
Baseline, mg/cm ³	11	1015 ± 44		32	1027 ± 50			
% Δ 6 months	11	-0.45 (-1.59, 0.70)	0.588	27	-1.59 (-2.50, -0.68)	0.001	1.14 (-0.42, 2.71)	0.202
% Δ 12 months	11	-3.21 (-5.42, -0.99)	<0.001	24	-1.82 (-2.78, -0.86)	<0.001	-1.39 (-3.33, 0.56)	0.130
I_{polar}								
Baseline, mg/cm	11	467 ± 115		32	433 ± 103			
% Δ 6 months	11	-3.73 (-6.79, -0.66)	0.053	27	-1.10 (-3.71, 1.52)	0.479	-2.63 (-7.06, 1.80)	0.130
% Δ 12 months	11	-3.98 (-9.68, 1.72)	0.036	24	-1.99 (-4.16, 0.18)	0.157	-1.99 (-6.69, 2.71)	0.207

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model, ^b Percent change calculated from absolute change in natural log transformed data. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation; vBMD, volumetric bone mineral density; BSI, bone strength index; I_{polar}; density-weighted polar cross-sectional moment of inertia.

Supplementary Table 7. Mean weight, total body lean mass, appendicular lean mass and total body fat mass at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months for participants with exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
Weight								
Baseline, Kg	11	81.1 \pm 9.0		36	89.3 \pm 17.6			
Δ 6 months	11	0.95 (-0.40, 2.29)	0.103	31	0.36 (-0.62, 1.33)	0.505	0.59 (-1.19, 2.37)	0.487
Δ 12 months	11	1.78 (0.24, 3.32)	0.002	29	-0.09 (-1.38, 1.21)	0.886	1.87 (-0.39, 4.12)	0.039
Total body lean mass								
Baseline, Kg	11	50.3 \pm 3.3		36	54.5 \pm 6.8			
Δ 6 months	11	0.98 (-0.15, 2.12)	0.013	30	-0.18 (-0.64, 0.28)	0.504	1.16 (0.19, 2.13)	0.021
Δ 12 months	11	0.69 (-0.17, 1.54)	0.084	29	-0.31 (-1.01, 0.39)	0.222	1.00 (-0.23, 2.22)	0.044
Appendicular lean mass								
Baseline, Kg	11	23.4 \pm 2.1		36	25.0 \pm 3.8			
Δ 6 months	11	0.49 (-0.45, 1.44)	0.107	30	-0.02 (-0.26, 0.22)	0.875	0.51 (-0.13, 1.16)	0.082
Δ 12 months	11	0.22 (-0.37, 0.80)	0.481	29	-0.30 (-0.65, 0.06)	0.033	0.51 (-0.15, 1.17)	0.082
Total body fat mass								
Baseline, Kg	11	27.4 \pm 6.5		36	31.5 \pm 12.3			
Δ 6 months	11	0.03 (-0.65, 0.72)	0.932	30	0.59 (-0.34, 1.53)	0.221	-0.56 (-2.14, 1.02)	0.508
Δ 12 months	11	1.20 (0.15, 2.25)	0.003	29	0.19 (-0.91, 1.28)	0.591	1.01 (-0.85, 2.88)	0.223

Baseline values represent means \pm SD and change values represent means with 95% confidence intervals (CI). Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation.

Supplementary Table 8. Mean muscle strength and physical function at baseline, absolute within-group changes from baseline and the net between-group differences for the change from baseline to 6- and 12-months for participants with exercise adherence $\geq 66\%$ and supplement adherence $\geq 80\%$.

	Ex+Suppl			Control			Net Difference (95% CI)	P-value
	n	Mean \pm SD or (95% CI)	P-value	n	Mean \pm SD or (95% CI)	P-value		
Muscle strength								
Leg press 3RM								
Baseline, Kg	11	148.6 \pm 29.9		29	136.4 \pm 54.0			
Δ 6 months	11	15.9 (-7.7, 39.5)	0.096	23	3.8 (-2.1, 9.7)	0.291	12.1 (-4.8, 29.0)	0.168
Δ 12 months	11	29.8 (2.1, 57.5)	0.002	20	7.5 (0.0, 15.0)	0.036	22.3 (1.2, 43.3)	0.012
Chest press 3RM								
Baseline, Kg	10	34.5 \pm 7.0		25	38.9 \pm 10.6			
Δ 6 months	10	3.2 (-1.5, 7.9)	0.025	22	-1.3 (-3.0, 0.5)	0.189	4.5 (0.6, 8.3)	0.009
Δ 12 months	10	2.7 (-0.6, 6.1)	0.054	18	0.1 (-2.5, 2.7)	0.942	2.6 (-1.5, 6.7)	0.118
Seated row 3RM								
Baseline, Kg	11	45.6 \pm 8.8		26	48.3 \pm 10.3			
Δ 6 months	11	3.3 (-2.1, 8.6)	0.101	20	0.5 (-1.6, 2.5)	0.607	2.8 (-1.7, 7.3)	0.173
Δ 12 months	11	4.1 (-1.3, 9.5)	0.041	17	0.8 (-1.9, 3.5)	0.626	3.3 (-1.9, 8.5)	0.082
Physical function								
30-second sit-to-stand								
Baseline, repetitions	11	13.5 \pm 5.5		36	12.6 \pm 3.8			
Δ 6 months	11	0.2 (-2.5, 2.8)	0.841	31	-0.8 (-1.7, 0.2)	0.127	1.0 (-1.1, 3.1)	0.358
Δ 12 months	11	-1.0 (-3.1, 1.1)	0.269	28	-1.4 (-2.4, -0.4)	0.005	0.4 (-1.6, 2.4)	0.819

Timed up-and-go with cognitive task

Baseline, seconds	11	10.95 ± 3.04		36	11.83 ± 4.48			
Δ 6 months	11	-0.07 (-2.11, 1.96)	0.947 ^a	31	-0.27 (-1.78, 1.24)	0.654 ^a	0.20 (-2.55, 2.94)	0.777 ^a
Δ 12 months	11	0.29 (-1.62, 2.20)	0.820 ^a	29	-0.55 (-2.17, 1.07)	0.742 ^a	0.84 (-1.98, 3.66)	0.730 ^a

Four square step test

Baseline, seconds	11	9.56 ± 1.69		36	9.62 ± 2.25			
Δ 6 months	11	-1.31 (-2.27, -0.35)	<0.001	31	-0.08 (-0.54, 0.37)	0.684	-1.23 (-2.14, -0.31)	0.003
Δ 12 months	11	-1.30 (-2.11, -0.49)	<0.001	29	-0.03 (-0.54, 0.47)	0.918	-1.27 (-2.19, -0.34)	0.001

Gait speed

Baseline, m/s	11	1.41 ± 0.16		33	1.43 ± 0.22			
Δ 6 months	11	0.04 (-0.03, 0.10)	0.161 ^a	28	-0.02 (-0.07, 0.03)	0.671 ^a	0.06 (-0.03, 0.14)	0.209 ^a
Δ 12 months	11	0.03 (-0.05, 0.11)	0.382 ^a	27	-0.01 (-0.07, 0.05)	0.776 ^a	0.04 (-0.06, 0.14)	0.428 ^a

400m walk

Baseline, seconds	11	271.60 ± 37.12		33	290.9 ± 37.7			
Δ 6 months	11	21.7 (-10.1, 53.6)	0.120 ^a	30	9.7 (-0.6, 20.1)	0.060 ^a	12.0 (-12.2, 36.1)	0.252 ^a
Δ 12 months	11	20.4 (-22.4, 63.2)	0.143 ^a	26	12.1 (0.1, 24.2)	0.049_a	8.2 (-22.7, 39.2)	0.325 ^a

Berg balance

Baseline, score	11	55.5 ± 0.8		36	54.3 ± 2.6			
Δ 6 months	11	0.2 (-0.5, 0.8)	0.430	31	-0.4 (-1.1, 0.4)	0.359	0.6 (-0.8, 1.9)	0.394
Δ 12 months	11	0.2 (-0.4, 0.8)	0.430	29	-0.03 (-0.5, 0.4)	0.966	0.2 (-0.6, 1.0)	0.728

Baseline values represent means ± SD and change values represent means with 95% confidence intervals (CI). ^a P-values from generalised linear mixed model. Ex+Suppl, multi-component exercise program combined with protein, calcium and vitamin D supplementation; 3RM, three repetition maximum.